Medtronic’s (MDT) Outperform Rating Reiterated at Royal Bank Of Canada

Medtronic (NYSE:MDT)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a research note issued on Wednesday, Benzinga reports. They presently have a $118.00 target price on the medical technology company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 28.37% from the company’s current price.

Several other equities analysts have also recently commented on the stock. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Monday, August 10th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a research note on Thursday, June 4th. Sanford C. Bernstein reduced their price target on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, June 4th. Mizuho decreased their price target on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Wednesday, June 3rd. Finally, Robert W. Baird increased their price objective on Medtronic from $91.00 to $100.00 and gave the stock a “neutral” rating in a research report on Wednesday. Nineteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $102.36.

Medtronic Trading Up 1.4%

Shares of Medtronic stock opened at $91.92 on Wednesday. Medtronic has a 52-week low of $73.31 and a 52-week high of $106.33. The stock’s 50-day simple moving average is $86.03 and its 200 day simple moving average is $85.42. The stock has a market capitalization of $117.66 billion, a P/E ratio of 24.64, a P/E/G ratio of 2.43 and a beta of 0.56. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same period last year, the company earned $1.26 earnings per share. The business’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, research analysts anticipate that Medtronic will post 5.94 EPS for the current year.

Insider Activity

In related news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Medtronic

Large investors have recently modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares during the last quarter. Jump Financial LLC bought a new stake in Medtronic in the second quarter worth $299,000. Main Street Financial Solutions LLC boosted its position in Medtronic by 28.9% during the second quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after buying an additional 3,218 shares during the period. Finally, HUB Investment Partners LLC boosted its position in Medtronic by 21.3% during the second quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock valued at $1,676,000 after buying an additional 3,376 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q1 results exceeded expectations. Medtronic reported adjusted EPS of $1.45 versus the $1.39 consensus estimate, while revenue rose 13.7% year over year to $9.76 billion, topping estimates of approximately $9.55 billion. Growth was broad-based, led by cardiovascular revenue of $3.93 billion, up nearly 19% organically. Medtronic fiscal first-quarter results
• Positive Sentiment: Full-year guidance was raised. Medtronic increased fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00, with management citing strong demand for cardiovascular devices, newer growth platforms and improved margins. Medtronic raises fiscal 2027 forecast
• Positive Sentiment: Robotics expansion strengthens Medtronic’s growth strategy. The company plans to invest approximately $700 million in Hong Kong-based Cornerstone Robotics and obtain rights to distribute its Sentire surgical system in select approved markets outside the U.S. The system will complement Medtronic’s Hugo robotic platform, broadening its minimally invasive surgery offering. Medtronic Cornerstone Robotics partnership
• Positive Sentiment: Additional structural-heart investment supports future products. Medtronic will invest up to $80 million in Pi-Cardia, securing an option to strengthen its technology portfolio for complex transcatheter aortic valve replacement procedures. Analysts at William Blair reiterated a Buy rating, while BTIG raised its price target from $91 to $100.
• Neutral Sentiment: Second-quarter fiscal 2027 EPS guidance of $1.32-$1.34 was slightly below the $1.35 consensus, although full-year guidance remained broadly in line with expectations after the increase.
• Neutral Sentiment: The quarter benefited from an additional fiscal week, which contributed approximately $570 million to organic revenue, creating a comparison factor investors may monitor in coming periods.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).